---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-064144"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-06-02T20:00:20+00:00"
generated_at: "2026-06-02T20:01:12.246613+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial

## Summary
- XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).
- Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).
- FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.
- No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.
- Complete dataset to be presented at AAIC 2026 (July 12-15, London).

## SEC filing metadata
- accession: 0001213900-26-064144
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-06-02T20:00:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/0001213900-26-064144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-064144
- JSON: https://secwatch.observer/filing/0001213900-26-064144.json
- Plain text: https://secwatch.observer/filing/0001213900-26-064144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.